Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia

(2009) Paul M. Armistead et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease

(2009) S. Parmar et al.   BLOOD

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

(2009) Elias Jabbour et al.   CANCER

Second hematopoietic stem cell transplantation in myeloid malignancies

(2009) Lisa M Arfons et al.   CURRENT OPINION IN HEMATOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy

(2008) L. Hambach et al.   BLOOD

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

(2008) M Campoli et al.   ONCOGENE